1 month ago
Indian Pharma Seeks US Engagement After Trump's Tariff Plan
The Indian pharmaceutical industry is worried about new tariffs announced by US President Donald Trump.
These tariffs will start in 2028 and will make it more expensive to import generic medicines to the US.
India supplies a lot of these medicines to the US, so the tariffs could affect both countries.
Indian companies have been working with the US and have set up factories there.
They are asking the US government to think about how these tariffs might make medicines more expensive for American patients.
The US wants to make more medicines in America, but Indian companies say they are already helping and want to keep working together.
Indian pharma industry seeks engagement with the US administration over proposed tariffs on generic medicines.
Trump's plan includes zero tariffs until August 1, 2028, then 100% for one year, and 200% thereafter.
India supplies 40-45% of all generic medicines dispensed in the US.
Indian companies have invested in US facilities and support American jobs.
Tariffs could increase healthcare costs and affect patient affordability in the US.
- Who
- Indian pharmaceutical industry and US administration
- What
- Proposed tariffs on imported generic medicines
- Where
- United States and India
- When
- Tariffs to take effect after August 1, 2028
- Why
- To reshore generic pharmaceutical production to America and ensure affordable medicine supplies
Indian Pharmaceutical Industry
US Administration
Tariff Impact
Indian Pharmaceutical Industry
Indian pharma companies express concern over potential tariffs, highlighting their role in supplying affordable medicines to the US.
US Administration
US administration aims to reshore generic pharmaceutical production to America, imposing tariffs to incentivize domestic manufacturing.
Investment and Jobs
Indian Pharmaceutical Industry
Indian companies have invested in US facilities and support American jobs, arguing for policy flexibility.
US Administration
US policy seeks to penalize companies that do not establish manufacturing facilities in the US during the transition period.
Key facts
- US Market Share
- Nearly a third of India's drug exports by value
- Generic Medicines Supply
- 40-45% of all generic medicines dispensed in the US
- Tariff Timeline
- Zero tariffs until August 1, 2028; 100% tariff for one year, then 200% thereafter
- Indian Pharma Facilities in the US
- Over 40 facilities
- Generic Medicines in US
- 90% of prescriptions dispensed, 13% of prescription drug spending
Quotes
Priyanka Chigurupati
Executive Director, Granules India
“India has been a trusted partner in ensuring the supply of affordable and quality‑assured medicines for American patients. Leading Indian pharmaceutical companies have a US presence, with over 40 facilities, supporting American jobs and investing in manufacturing, research and resilient supply chains.”
businesstoday.in
“Granules supports the goal of building a more resilient pharmaceutical supply chain. Through our three US facilities, including one manufacturing facility with the ability to expand capacity, we have invested in strengthening our US footprint and are well positioned to support increased onshoring.”
businesstoday.in
Sources
Related news
Volvo ES90 And EX90 Electric Flagships Launch In India
Gujarat launches DNA-based sports talent hunt for 2030 Commonwealth Games
Bengaluru Engineers Develop Affordable AI PC KEO
Volvo EX90 and ES90 India Launch Set for October 12
Nvidia’s RTX Spark AI PCs From Lenovo, Acer Launch October
Scotland, Wales and Northern Ireland Leaders Seek Referendum Rights
Ajit Mishra Recommends Trades in Granules, HAL and HUL Shares
GIFT Nifty Signals Gap-Down Start as Crude Rises
Granules India Focuses on Injectables and M&A
Hyderabad Firm Gets US Nod for Generic ADHD Drug
